Allergan USA Inc.

Allergan USA Inc., a non-small-business subsidiary of AbbVie Inc. (formerly Allergan, Inc.), operates as the sole-source federal supplier of Natrelle-branded breast implants and reconstructive surgical devices to the Department of Defense, Veterans Affairs, and Indian Health Service through a $13.5 million single-award Indefinite Delivery Contract established December 8, 2022, with the Defense Logistics Agency Troop Support Medical Supply Chain. The company manufactures and delivers breast implant systems, tissue expanders, and associated surgical instruments (Keller Funnels, sizers, needle infusion sets) from its Irvine, California headquarters, competing full-and-open with no SBA set-aside posture across 812 recent federal awards.

Allergan USA Inc.'s federal footprint is overwhelmingly concentrated in the Defense Logistics Agency Medical Supply Chain, which accounts for 564 awards (70% of the active portfolio) worth $57.5 million in combined potential value, with delivery orders issued monthly ranging from approximately $200 to $24,000 per order. The top five customer organizations by award count represent 84% of recent awards: the Defense Logistics Agency dominates by volume; the Department of Veterans Affairs Veterans Integrated Service Networks (VISN 7, VISN 8, VISN 6, and others) collectively place moderate-value orders for individual implant configurations; the Department of the Navy Bureau of Medicine and Surgery, Department of the Air Force Materiel Command Test Center, and Department of the Army Medical Command round out active purchasers. By potential value, however, Veterans Integrated Service Network 12 carries $8.8 billion in combined potential value across only three awards, signaling either large blanket or requirement contracts; the Defense Logistics Agency's $57.5 million ranks second. Activity has grown sharply—27 awards in 2022, rising to 181 in 2025 and 127 year-to-date in 2026—reflecting consistent electronic catalog ordering velocity under the parent IDVs.

Allergan USA Inc. holds two principal parent vehicles, both single-award indefinite delivery contracts with DLA Troop Support Medical established December 8, 2022: a $13.5 million IDV (ceiling $13,467,837.92, ultimate completion November 20, 2027) for Natrelle breast implants and surgical devices, and a $4.9 million IDV for Allergan Aesthetics surgical items (ceiling $4,900,000, ultimate completion December 7, 2023). The larger Natrelle IDV has generated 529 task orders worth $1.5 million in combined potential value; the aesthetics vehicle carried 32 task orders totaling $959 thousand. Both employ fixed-price delivery order pricing with economic price adjustment and support electronic catalog ordering with on-site Allergan technical support across Department of Defense research centers, hospitals, and clinics. Allergan USA Inc. also receives direct purchase orders from individual Veterans Affairs Medical Centers (evidenced by a $15,758.79 prosthetic implant order from VISN 2 on August 28, 2025).

The capability portfolio centers narrowly on Natrelle-branded breast implants in multiple configurations (Inspira models in SCX, SCF, SCM, SSM, SSF variants; TE Smooth tissue expanders in numbered styles and sizes), surgical accessories (Keller Funnels sold in 5-count packs, single-use sizers, re-sterilizable sizers in various sizes, needle infusion sets), and implant sizing instruments. Recent delivery orders illustrate the breadth: a $2,850 order for Natrelle Inspira SSM 310CC implants (July 16, 2026); multiple orders for Inspira SCLP and SSLP variants at $1,200–$4,635 each; Natrelle TE Smooth 133S tissue expanders in multiple sub-variants at $1,495–$3,404; and Keller Funnels at $698–$2,094 per 5-count pack. All delivery orders carry fixed-price structures with economic price adjustment and no set-aside designation, reflecting Allergan's monopoly position as the federal supplier of these proprietary devices.

Allergan USA Inc. competes as a prime contractor exclusively; the source contains no subcontract awards. The company operates at scale—812 recent federal awards with $8.88 billion in combined potential value—but the dollar concentration is driven by three large VISN 12 awards rather than by the numerous DLA Medical Supply Chain orders, which individually are under $25,000. The top NAICS categories across the portfolio are Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (533 awards) and Surgical Appliance and Supplies Manufacturing (125 awards), aligning with Allergan's role as both a manufacturer and distributor of implant devices. All work is performed in Irvine, California.

Allergan USA Inc. is a child entity of Allergan, Inc. (parent, for-profit manufacturer, headquartered Lake Bluff, Illinois), which in turn is now owned by AbbVie Inc. (multinational pharmaceutical and healthcare company). The subsidiary's federal contracting activity is discrete and specialized: no evidence of prime subcontracting, no participation in government-wide vehicles outside the DLA IDVs, and no grant work. Recompete exposure is minimal in the near term because the parent $13.5 million DLA IDV does not reach ultimate completion until November 20, 2027, and all task orders under it are issued on a non-competitive sole-source basis reflecting Allergan's position as the exclusive federal supplier of Natrelle breast implants and related reconstructive surgical devices to the military healthcare enterprise.